6 newsletters, ranked by editorial quality and how recently they published. Looking for something more specific? Search instead.
Future Insider is a Substack newsletter examining the economics and science of AI and emerging technology, including AI infrastructure investing, IPO risk, and AI in drug trials. Readers get analytical essays on which AI-driven businesses and tools may succeed and what the market is pricing in.
Independent investment research covering longevity biotech, diagnostics, robotics and alternative energy, with structured TL;DR, problem, solution and thesis sections. Issues weigh company catalysts, trial data and financials against what has not yet been proven.
Alex Kesin's blog-style newsletter examines biotech and drug development, from US-China competition in drug licensing to pharma share buybacks and the heavy-tailed revenue distributions shared by drugs and Hollywood films. Readers get long-form, opinionated analysis with data, historical context and wry commentary on industry dynamics.
Tracks small and mid-cap biotech companies seen as potential acquisition targets, with M&A and growth scores, catalysts, risks and valuation commentary drawn from conference presentations. Also includes occasional market history posts.
A physician-commentator shares opinionated takes on medicine, health policy, AI and current events, including film reviews and news-driven analysis. Readers get a skeptical, evidence-focused perspective on topics like cancer screening, biotech claims and healthcare policy.
Contrary Research publishes profiles and analysis of private tech companies, plus short news-style issues on AI, big tech and science. The sample mixes a substantive essay on AI benchmarks and Goodhart's Law with brief, factual news roundups that mostly relay reported claims.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
